Author: Peter

Hospitals and health system pharmacists are urging the Biden administration to review insurer "white bagging" policies...Payers use white bagging to dispense drugs to hospitals, requiring these medications come from select network specialty pharmacies. AHA and ASHP said in the letter that doing so circumvents hospital supply chain protocols aimed at patient safety..."White bagging has surged in frequency over the past decade, creating what amounts to a shadow inventory that hospitals and health systems do not legally own and which exists largely outside of the DSCSA’s track and trace requirements,"...READ MORE

A new legislation recently passed by the Michigan’s House of Representatives would require reforms to many pharmacy benefit manager reimbursement practices in the state...The provisions listed in HB 4348 would prohibit PBMs from reimbursing pharmacies affiliated with the PBM more than non-affiliate pharmacies; prohibit patient steering to PBM-owned pharmacies; prohibit retroactive clawbacks; require reimbursement be based on the National Average Drug Acquisition Cost; and establish fair audit procedures for community pharmacies...READ MORE

In their clinical trials, the Pfizer and Moderna vaccines did okay, well enough for the FDA to grant emergency use authorization. But in a real-world study, where participants were all on the front lines fighting Covid, the vaccines proved 90% effective against the virus – not just the symptomatic disease. In the clinical studies, Pfizer and Moderna were testing against disease...According to the CDC-sponsored study released today, it didn’t matter which vaccine the participants received. What mattered was that both vaccines were designed using messenger RNA to repel the coronavirus. The results showed that the vaccines were even effective against asymptomatic virus...READ MORE

In an unusual move... officials with the National Institute of Allergy and Infectious Diseases urged AstraZeneca to ensure it is providing the most recent efficacy data on its coronavirus vaccine. The statement came 1 day after the manufacturer released interim data from its U.S. trials...NIAID...said an independent monitoring board informed it that AstraZeneca's disclosures of the study results may have been based on outdated evidence. The agency's response to the company...READ MORE

Workers at an Emergent BioSolutions plant in Baltimore mixed up vaccine ingredients weeks ago and ruined a large batch of the vaccine containing up to 15 million doses...The FDA is investigating the mistake, but the episode has led to a temporary halt of future J&J shot deliveries from the site...In a statement, J&J said it's working with federal authorities to deliver 24 million doses of the vaccine in April...The mistake happened early in the production process, so none of the doses made it out to distribution...READ MORE

Here's a look at how it was created, what it offers – and how it grew to reach more than 38 million visits in seven months...Amid the COVID-19 pandemic, Johns Hopkins Medicine needed to provide accurate content very quickly in an information environment that was changing by the hour...In a pre-pandemic world, the organization's content team would look to search engine optimization strategies to see what questions people are asking and determine what information would be most useful. However, that data was just not yet available for COVID-19 when the pandemic hit...READ MORE

AstraZeneca created a COVID-19 vaccine data controversy this week by reportedly selecting the most favorable data to tout on its program, a move independent data monitors publicly flagged in a middle-of-the-night missive. Now, with a speedy data update and analysis, AstraZeneca says it can “confirm” the vaccine’s phase 3 success...In a newly released primary analysis, AstraZeneca says its vaccine was 76% effective against symptomatic COVID-19 and 85% effective against symptomatic disease in people 65 and over. The shot was also 100% effective against severe disease and hospitalization in the phase 3 trial...READ MORE

Eli Lilly faced a high-level personnel scandal last month when CFO Josh Smiley left under a cloud of "inappropriate" communications with employees. But a sex discrimination lawsuit from a former internal lobbyist uncovers an entirely new controversy—and offers an alleged look inside the culture of a key team...Sonya Elling, a longtime biopharma lobbyist who worked in Lilly's government affairs operation, sued the company alleging mistreatment by her supervisors on the basis that she is a female...During Elling's time at the company, her first- and second-level supervisors called her “mean,” “nasty,” “disruptive,” “rude,” “aggressive,” and a “bitch,” according to the suit. They did so because she is a "strong, assertive female," who didn't "conform to traditional gender stereotypes," the suit says...READ MORE

Forged vaccination certificates and fake negative tests are also reportedly available for purchase on the black market...The World Health Organization...issued a warning about counterfeit and stolen COVID-19 vaccines being sold on the dark web...Fake vaccination certificates are also being sold, as well as fake negative tests, aimed at those traveling abroad...The WHO is "aware of vaccines being diverted and reintroduced into the supply chain, with no guarantee that [the] cold chain has been maintained...READ MORE

Democrats...are united behind an idea that Republican lawmakers and major drugmakers fiercely oppose: empowering the Department of Health and Human Services to negotiate the prices of brand-name drugs covered by Medicare...Democrats hope to authorize Medicare negotiations on payments for at least some of the most expensive brand-name drugs and to base those prices on the drugs’ clinical benefits...READ MORE